Non-canonical fibroblast growth factor signalling in angiogenesis
- PMID: 18056763
- DOI: 10.1093/cvr/cvm086
Non-canonical fibroblast growth factor signalling in angiogenesis
Abstract
Whereas fibroblast growth factors (FGFs) classically transmit their signals via high-affinity tyrosine kinase receptors (FGFR1-4), recent evidence strongly implicates non-tyrosine kinase receptors (NTKR) or cell-surface FGFR-interacting proteins as important players in FGF signalling. Although NTKR have lower affinity for FGFs in comparison with cognate tyrosine kinase receptors, because of their high abundance they can effectively bind FGFs and produce unique biological effects independent of FGFRs. A prime example of such NTKR is the syndecan family of plasma membrane proteoglycans and, in particular, syndecan-4, which transmits FGF signalling via a protein kinase Calpha pathway. Another NTKR, alpha(v)beta(3) integrin, functions as an FGF signalling modulator by binding both FGF2 and FGFR1. Yet another NTKR, neural cell adhesion molecule (NCAM), can serve as an FGFR ligand and assemble an FGFR signalling complex in the absence of FGFs. Furthermore, N-cadherin, which has been reported to associate with FGFR, appears to activate FGFR in both ligand (FGF)-dependent and ligand-independent manners. Finally, gangliosides are implicated as a co-receptor system of FGFs. The biological consequence of non-canonical FGF signalling tends to be less discernable compared to the canonical FGFR activation because of the overlap between these two pathways; nevertheless, non-canonical signalling is important and sometimes essential for cellular functions. Given the diversity of FGF activities through embryonic development to adult physiology, the existence of the non-canonical signalling system may account for the different cellular response to the FGF input in different biological contexts. In this review, we will discuss recent findings related to non-canonical FGF signalling with emphasis on the endothelial biology and angiogenesis.
Similar articles
-
The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic _target in tumor angiogenesis.Expert Opin Ther _targets. 2015;19(10):1361-77. doi: 10.1517/14728222.2015.1062475. Epub 2015 Jun 30. Expert Opin Ther _targets. 2015. PMID: 26125971 Review.
-
Glycosylation of FGF/FGFR: An underrated sweet code regulating cellular signaling programs.Cytokine Growth Factor Rev. 2024 Jun;77:39-55. doi: 10.1016/j.cytogfr.2024.04.001. Epub 2024 May 3. Cytokine Growth Factor Rev. 2024. PMID: 38719671 Review.
-
Identification of residues important both for primary receptor binding and specificity in fibroblast growth factor-7.J Biol Chem. 2000 Nov 10;275(45):34881-6. doi: 10.1074/jbc.M003293200. J Biol Chem. 2000. PMID: 10950949
-
FGF signalling through RAS/MAPK and PI3K pathways regulates cell movement and gene expression in the chicken primitive streak without affecting E-cadherin expression.BMC Dev Biol. 2011 Mar 21;11:20. doi: 10.1186/1471-213X-11-20. BMC Dev Biol. 2011. PMID: 21418646 Free PMC article.
-
Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly.Biochemistry. 2004 Apr 27;43(16):4724-30. doi: 10.1021/bi0352320. Biochemistry. 2004. PMID: 15096041
Cited by
-
Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis.Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13379-84. doi: 10.1073/pnas.1324235111. Epub 2014 Aug 19. Proc Natl Acad Sci U S A. 2014. PMID: 25139991 Free PMC article.
-
Cooperation between AlphavBeta3 integrin and the fibroblast growth factor receptor enhances proliferation of Hox-overexpressing acute myeloid leukemia cells.Onco_target. 2016 Aug 23;7(34):54782-54794. doi: 10.18632/onco_target.10189. Onco_target. 2016. PMID: 27340869 Free PMC article.
-
FGFR4: A promising therapeutic _target for breast cancer and other solid tumors.Pharmacol Ther. 2020 Oct;214:107590. doi: 10.1016/j.pharmthera.2020.107590. Epub 2020 May 31. Pharmacol Ther. 2020. PMID: 32492514 Free PMC article. Review.
-
_target identification for CNS diseases by transcriptional profiling.Neuropsychopharmacology. 2009 Jan;34(1):18-54. doi: 10.1038/npp.2008.172. Epub 2008 Oct 15. Neuropsychopharmacology. 2009. PMID: 18923405 Free PMC article. Review.
-
Allosteric _targeting of receptor tyrosine kinases.Nat Biotechnol. 2014 Nov;32(11):1113-20. doi: 10.1038/nbt.3028. Nat Biotechnol. 2014. PMID: 25380447
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous